Summary
Cannot assess alignment because the prompt contains no FDA label excerpt text for several specific claims (e.g., aspirin/beta blockers/ACE inhibitors), and other claims cannot be verified against the provided excerpts with enough specificity. Several drug-interaction claims are either not present or are not supported by the supplied label text.
Category Scores
Accurate Statements
Lipitor is a statin that works by inhibiting the production of cholesterol in the liver.
Supported by Section 12.1 mechanism: “LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase…”
Unsupported Statements
Lipitor is a cholesterol-lowering medication used to treat high cholesterol.
Not directly supported by the provided excerpt wording. Section 1.2 indicates use in hyperlipidemia/dyslipidemia as an adjunct to diet, but the exact phrasing “treat high cholesterol” is not explicitly present in the supplied excerpts.
Lipitor reduces the risk of heart disease.
The provided label excerpts specify reductions in myocardial infarction, stroke, revascularization procedures, angina, and related outcomes (Section 1.1), but do not explicitly use the phrase “heart disease.”
Taking Lipitor with anticoagulants increases the risk of bleeding.
No anticoagulant/bleeding interaction is included in the provided label excerpts (Section 7 interactions excerpt provided does not mention anticoagulants).
Taking Lipitor with antiplatelet agents increases the risk of bleeding.
No antiplatelet/bleeding interaction is included in the provided label excerpts (Section 7 excerpt does not mention antiplatelet agents).
Taking Lipitor with NSAIDs increases the risk of bleeding.
NSAIDs/bleeding interaction is not included in the provided label excerpts.
Taking Lipitor with cyclosporine reduces the effectiveness of cyclosporine.
Provided label excerpts state a dosing limitation for cyclosporine and increased risk of myopathy/rhabdomyolysis with cyclosporine, but do not state cyclosporine effectiveness is reduced (Sections 2.6 and 5.1/7).
Taking Lipitor with cyclosporine can lead to kidney damage.
The label excerpt discusses rhabdomyolysis with acute renal failure secondary to myoglobinuria (Section 5.1). It does not directly state cyclosporine causes kidney damage; the claim is more specific than the supplied excerpt supports.
Taking Lipitor with digoxin can increase digoxin levels in the blood.
No digoxin interaction is included in the provided label excerpts.
Increased digoxin levels from taking Lipitor with digoxin can lead to toxicity.
This follows from the digoxin-level claim; the underlying digoxin interaction is not supported by supplied label excerpts.
Taking Lipitor with fibrates increases the risk of muscle damage.
The provided label excerpts state statin myopathy risk is increased with “fibric acid derivatives” (Section 7). However, the supplied excerpts do not explicitly say “fibrates” or “muscle damage” wording; support is partial but not explicitly aligned to the user’s phrasing.
Taking Lipitor with niacin increases the risk of muscle damage.
No niacin interaction is included in the provided label excerpts.
Taking Lipitor with other statins increases the risk of muscle damage.
No interaction specifically about combining with “other statins” is included in the provided label excerpts.
Taking Lipitor with niacin reduces the effectiveness of niacin.
No label support in the provided excerpts for reduced effectiveness of niacin.
Taking Lipitor with niacin can lead to increased cholesterol levels.
No label support in the provided excerpts for increased cholesterol levels with niacin when taken with Lipitor.
Taking Lipitor with warfarin increases the risk of bleeding.
No warfarin/bleeding interaction is included in the provided label excerpts.
Taking Lipitor with aspirin is generally safe.
No aspirin interaction/safety statement is included in the provided label excerpts.
When Lipitor is taken with aspirin, bleeding risk should be monitored.
No aspirin/bleeding monitoring guidance is included in the provided label excerpts.
Lipitor can be taken with beta blockers (e.g., metoprolol or atenolol) without significant interactions.
No beta-blocker interaction information is included in the provided label excerpts.
Lipitor can be taken with blood pressure medications (e.g., lisinopril or amlodipine) without significant interactions.
No lisinopril/amlodipine interaction information is included in the provided label excerpts.
Contradictions
Important Omissions
For interaction-related claims (e.g., anticoagulants, antiplatelets, NSAIDs, digoxin, warfarin, aspirin, beta blockers, ACE inhibitors/CCBs), the provided label excerpts do not include the relevant interaction sections; without those excerpts, accurate assessment cannot be made. If an AI response includes such claims, they should be omitted or limited to what the label excerpts explicitly cover.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple interaction claims are unsupported by the provided label excerpts (e.g., bleeding-risk interactions and digoxin/warfarin). Unsupported interaction guidance could mislead clinicians/patients.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many specific drug-interaction and safety assertions are not supported by the supplied label excerpts, and some are more specific than the cited mechanisms/warnings.
Suggested Improvement
Restrict interaction and risk statements to those explicitly supported by the provided label excerpts (e.g., cyclosporine dosing limit and increased myopathy risk; increased myopathy risk with fibric acid derivatives; cytochrome P450 3A4 inhibition effects). Omit or qualify claims (e.g., anticoagulants/antiplatelets/NSAIDs/digoxin/warfarin/aspirin/beta-blockers/ACEi/CCBs) when not present in the supplied label text.